Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease.

Research output: Contribution to journalArticle

Abstract

Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal dose for the fixed-dose combination of the LAMA tiotropium and the LABA olodaterol needed to be determined. In this phase II trial, the dose response of tiotropium on top of olodaterol was investigated in a free-dose combination, while other phase II studies have explored different doses of olodaterol on top of tiotropium, with both drugs delivered using the Respimat(®) inhaler.

Details

Authors
  • René Aalbers
  • M Reza Maleki-Yazdi
  • Alan Hamilton
  • Stella Waitere-Wijker
  • Yihua Zhao
  • Valeria C Amatto
  • Olaf Schmidt
  • Leif Bjermer
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Respiratory Medicine and Allergy
Original languageEnglish
Pages (from-to)809-822
JournalAdvances in Therapy
Volume32
Issue number9
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes